.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Deloitte
McKesson
US Army
Covington
Federal Trade Commission
Medtronic
McKinsey
Healthtrust
Accenture

Generated: June 24, 2017

DrugPatentWatch Database Preview

Fenofibrate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fenofibrate and what is the scope of fenofibrate freedom to operate?

Fenofibrate
is the generic ingredient in nine branded drugs marketed by Abbott, Abbvie, Cipla Ltd, Impax Labs, Cipher Pharms Inc, Valeant Pharms North, Aurobindo Pharma Ltd, Santarus Inc, Lupin Ltd, Mylan, Rhodes Pharms, Sun Pharm Inds Ltd, Skyepharma Ag, Apotex Inc, Mylan Pharms Inc, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Invagen Pharms, Lupin Atlantis, and Hetero Labs Ltd Iii, and is included in twenty-eight NDAs. There are nineteen patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Fenofibrate has three hundred and eighty-eight patent family members in forty-nine countries.

There are forty-two drug master file entries for fenofibrate. Fifty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: fenofibrate

Tradenames:9
Patents:19
Applicants:20
NDAs:28
Drug Master File Entries: see list42
Suppliers / Packagers: see list51
Bulk Api Vendors: see list80
Clinical Trials: see list138
Patent Applications: see list6,493
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:fenofibrate at DailyMed

Pharmacology for Ingredient: fenofibrate

Tentative approvals for FENOFIBRATE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe43MGCAPSULE; ORAL
► Subscribe► Subscribe130MGCAPSULE; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-003Sep 4, 2001DISCNYesNo6,589,552► Subscribe ► Subscribe
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-003Sep 4, 2001DISCNYesNo7,037,529► SubscribeY ► Subscribe
Glenmark Pharms Ltd
FENOFIBRATE (MICRONIZED)
fenofibrate
CAPSULE;ORAL205566-001Apr 7, 2017ABRXNoNo► Subscribe► Subscribe
Santarus Inc
FENOGLIDE
fenofibrate
TABLET;ORAL022118-001Aug 10, 2007ABRXYesNo7,658,944► SubscribeY ► Subscribe
Impax Labs
FENOFIBRATE
fenofibrate
TABLET;ORAL076509-001Mar 26, 2008ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fenofibrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
TRICOR (MICRONIZED)
fenofibrate
CAPSULE;ORAL019304-003Jun 30, 19994,895,726► Subscribe
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-003Sep 4, 20014,895,726► Subscribe
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 20014,895,726► Subscribe
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-003Nov 30, 20044,800,079► Subscribe
Cipher Pharms Inc
LIPOFEN
fenofibrate
CAPSULE;ORAL021612-003Jan 11, 20065,545,628► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fenofibrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,592,903 Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate► Subscribe
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► Subscribe
7,695,739In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
6,534,088 Fibrate-statin combinations with reduced fed-fasted effects► Subscribe
8,586,094Coated tablets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fenofibrate

Country Document Number Estimated Expiration
Japan4841092► Subscribe
Canada2440355► Subscribe
Australia731964► Subscribe
Canada2372561► Subscribe
Japan2005206614► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Harvard Business School
Fish and Richardson
QuintilesIMS
UBS
Covington
Argus Health
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot